|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.00 / 0.00|
Actelion was too pricey. Now J&J is looking for another acquisition.
One of these biopharma executives, or the grouped nominees, will win the Swanson Trophy, named in honor of Robert Swanson, Genentech's founding CEO. Here are the best biopharma CEOs.
Today's spike in oil prices was even strong enough to embolden money managers to do some buying, Cramer says.
Jim Cramer shares his views on the latest moves in biotech and retail. Account, Regeneron, Burlington Stores and Five Below are among the many stocks discussed here.
Health care deals dominate the list of big mergers so far this year, while tech comes in second.
Jim Cramer likes the 10 early-stage drugs J&J has in its pipeline, among other reasons.
Jim Cramer reveals why his Action Alerts PLUS charitable trust portfolio is initiating coverage of Johnson & Johnson (JNJ) on Tuesday.
Trade-Ideas LLC identified Pharmacyclics (PCYC) as a new lifetime high candidate
The Fed chief used some pretty frightening terms about stocks Wednesday, saying that valuations 'generally are quite high' and that there are 'potential dangers' with them.
Mega deals from strategic players across a variety of industries pushed first-quarter deals to the highest value since 2007.
The drug companies' strengths in generics and knocks-off drugs should complement one another.
Mylan made public on Wednesday that it had made a proposal to acquire generic drugmaker Perrigo in a deal valued at $205 per share in cash and stock.
Neither of the deals announced Monday are blockbusters or particularly transformative. Both buyers have specific needs and went after small targets for large prices.
Catch up on Jim Cramer's thinking over the last week about two leadership groups that have been hammered and the spike in oil.
The shares of BioMarin are climbing after a blog reported last night that Shire is considering offering to acquire the company.
TheStreet Ratings team reiterated 3 stocks with a hold rating on Thursday
If history repeats itself, the recent weakness in biotech stocks will end with lots more buying.
It shouldn't be possible, but it never seems too late to get in.
It's creating investment opportunities that just shouldn't exist, Cramer says.
Jim Cramer's charitable trust closed out its position in AbbVie on Tuesday, citing concerns for its 'expensive' acquisition plans for Pharmacylics.
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Pharmacyclics...
The following statement is being issued by Levi & Korsinsky, LLP: TO: ALL PERSONS OR ENTITIES WHO PURCHASED OR OTHERWISE ACQUIRED COMMON STOCK OF PHARMACYCLICS INC.
Catch up on Jim Cramer's thinking over the last week about the sheer power of execution and the much-needed bounceback in biotech.
Cramer says what seems overvalued on paper today might surprise you and be in a whole new category tomorrow.
Stocks manage to close with gains on Thursday, but just barely ahead of the February jobs report on Friday
Stocks regain positive momentum by mid-afternoon. Weaker-than-expected domestic data and the materials sector kept gains limited.
AbbVie agreed to buy Pharmacyclics for $261.25 per share, or $21B, the companies announced late last night.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.